

CHARGE: 501(c)—the strength of the article, when shipped, differed from that which it purported and was represented to possess, namely, 25,000 I. U. estrogens per cubic centimeter; 502(a)—the carton label statement "Per CC * * * Estrogens * * * 25,000 I. U." was false and misleading as applied to the article, which contained 21.6 percent of the declared amount of estrogens; 502(b) (1)—the label of the article failed to bear the name and place of business of the manufacturer, packer, or distributor; 502(b) (2)—the label of the article failed to bear an accurate statement of the quantity of contents; and 502(e) (2)—the label of the article failed to bear the common or usual name of each ingredient.

DISPOSITION: 8-9-57. Default—destruction.

5451. Pyrilamine maleate Prolongsules. (F.D.C. No. 40358. S. No. 41-858 M.)

QUANTITY: 1 drum containing 24,935 capsules, and 238 12-capsule vials at Buffalo, N.Y.

SHIPPED: 3-30-56, from Philadelphia, Pa., by Richlyn Laboratories.

LABEL IN PART: (Drum) "Pyrilamine Maleate Prolongsules * * * Delayed Action, Time Disintegrating Capsules * * * Released Gradually * * * Over A Period of Approximately 8 Hours * * * Each Prolongsule Contains: Pyrilamine Maleate 75 Mgm."

RESULTS OF INVESTIGATION: Analysis showed that the capsules of the article did not allow gradual release of pyrilamine maleate over a period of approximately 8 hours, but, instead, the pyrilamine maleate was released in a much shorter time. Examination showed that the capsules in vials had been repacked from the bulk drum.

LIBELED: 6-27-57, W. Dist. N. Y.

CHARGE: 501(c)—the quality of the article, when shipped, fell below that which it was represented to possess since the active ingredient was not gradually released over an 8-hour period, but was, instead, released in a much shorter time; and 502(a)—the statements in the label which represented and suggested that the active ingredient was gradually released over an 8-hour period were false and misleading.

DISPOSITION: 8-15-57. Default—destruction.

5452. Bennett Arben capsules. (F.D.C. No. 40199. S. Nos. 74-867/70 M.)

QUANTITY: 24,000 capsules of *Formula No. 2*, 23,000 capsules of *Formula No. 6A*, 24,000 capsules of *Formula No. 8A*, and 17,000 capsules of *Formula No. 12A* at Santa Monica, Calif. The capsules were packed in bulk drums.

SHIPPED: On an unknown date, from Miami Beach, Fla., by Arthur Bennett Pharmaceuticals.

LABEL IN PART: "Bennett Arben Capsules *Formula No. 2* * * * Amphetamine Sulfate 1.2 mgm. * * * Lot No. 2016," "Bennett Arben Capsules *Formula No. 6A* * * * Amphetamine Sulfate 1.8 mgm. * * * Lot. No. 3010," "Bennett Arben Capsules *Formula No. 8A* * * * Amphetamine Sulfate 2.5 mgm. * * * Lot No. 3008," and "Bennett Arben Capsules *Formula No. 12A* * * * Amphetamine Sulfate 5 mgm. * * * Lot No. 3014."

RESULTS OF INVESTIGATION: Examination showed that the capsules contained the following amounts of amphetamine sulfate per capsule: *Formula No. 2*—2.3 mgs., *Formula No. 6A*—3.3 mgs., *Formula No. 8A*—4.9 mgs., and *Formula No. 12A*—9.8 mgs.

LIBELED: 5-16-57, S. Dist. Calif.

CHARGE: 501(c)—the strength of the capsules, when shipped, differed from that which they purported and were represented to possess.

DISPOSITION: 7-2-57. Default—destruction.

5453. Hemoton Forte. (F.D.C. No. 40284. S. No. 81-743 M.)

QUANTITY: 75 10-cc. vials at Metairie, La.

SHIPPED: 12-18-56, from Decatur, Ill.

LIBELED: 6-17-57, E. Dist. La.

CHARGE: 501(c)—the strength of the article, while held for sale, differed from that which it was represented to possess, namely, 60 micrograms of cyanocobalamin per cubic centimeter; and 502(a)—the label statement "Each cc contains Vitamin B-12—(From Liver Injection) Equivalent To: Cyanocobalamin 10 mcgm—and Cyanocobalamin (added) 50 mcgm" was false and misleading as applied to an article which had a potency of less than 40 micrograms of cyanocobalamin per cubic centimeter.

DISPOSITION: 8-15-57. Default—destruction.

5454. Prophylactics. (F.D.C. No. 40361. S. No. 72-915 M.)

QUANTITY: 720 2-unit pkgs. at Evanston, Wyo.

SHIPPED: 6-18-57, from Brooklyn, N.Y., by J. Schoenbach.

LABEL IN PART: "Royal Knight Prophylactics."

RESULTS OF INVESTIGATION: Examination showed that 5.9 percent of the article was defective in that it contained holes.

LIBELED: 7-2-57, Dist. Wyo.

CHARGE: 501(c)—the quality of the article, when shipped, fell below that which it purported to possess; and 502(a)—the label statement "Prophylactics" was false and misleading as applied to an article that contained holes.

DISPOSITION: 8-22-57. Default—destruction.

DRUGS ACTIONABLE BECAUSE OF FALSE AND MISLEADING CLAIMS*

5455. Homeopathic drugs. (Inj. No. 298.)

COMPLAINT FOR INJUNCTION FILED: 3-27-56, E. Dist. Wis., against Louis Pauly, Milwaukee, Wis.

NATURE OF BUSINESS: The complaint alleged that the defendant was engaged in selling and distributing various *homeopathic drugs* in the form of tablets of various strengths and designated by name as follows: Calcium Fluoride (Calcarea Fluorica), Calcium Phosphate (Calcarea Phosphorica), Calcium Sulfate (Calcarea Sulphurica), Iron Phosphate (Ferrum Phosphate), Sodium Chloride (Natrum Muriaticum), Potassium Chloride (Kali Muriaticum), Sodium Sulfate (Natrum Sulphuricum), Silica (Silicea or Quartz), Potassium Phosphate (Kali Phosphate), Potassium Sulfate (Kali Sulphuricum), Magnesium Phosphate (Magnesium Phosphoricum), and Sodium Phosphate (Natrum Phosphoricum).

It was alleged that while these drugs were held for sale by the defendant, after shipment in interstate commerce, the defendant caused the drugs to be accompanied by the following pieces of labeling: Blotters entitled "Professional Comments on the Bio-Chemic System of Medicine" and "My Proposed Cover

*See also Nos. 5441, 5442, 5444-5451, 5453, 5454.